Physician profile
Ashley Douglas
NPI 1346842887
$4,727.88
in general payments reported to CMS, 2019-2025
34 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $337 · 2022: $472 · 2023: $1,142 · 2024: $1,306 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,919.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $936.93 | 2021-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $890.16 | 2021-2025 | Tezspire, Airsupra, Breztri |
| Amgen INC. | $532.46 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $493.93 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.58 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $188.68 | 2023-2025 | |
| Abbvie INC. | $135.70 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.20 | 2022-2024 | Glassia |
| Mallinckrodt Hospital Products INC. | $102.28 | 2022-2025 | Acthar |
| Merck Sharp & Dohme LLC | $91.02 | 2023-2025 | Zerbaxa, Keytruda |
| Ucb, INC. | $79.16 | 2023-2024 | Briviact |
| Mylan Specialty L.P. | $72.46 | 2021-2024 | Yupelri |
| Inogen, INC. | $64.92 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sk Life Science, INC. | $62.82 | 2023-2025 | |
| Viatris Specialty LLC | $59.81 | 2025 | Yupelri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $47.80 | 2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $43.11 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Ethicon INC. | $42.29 | 2022-2025 | Monarch Platform |
| Janssen Pharmaceuticals, INC | $42.29 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.99 | 2021-2022 | |
| Lilly USA, LLC | $39.88 | 2025 | Zepbound |
| Grifols USA, LLC | $39.10 | 2024 | Prolastin-C Liquid |
| Pfizer INC. | $38.53 | 2025 | |
| Eisai INC. | $38.42 | 2024-2025 | |
| Emd Serono, INC. | $31.61 | 2024 | |
| Astellas Pharma US INC | $24.65 | 2023 | Cresemba |
| Fisher & Paykel Healthcare INC | $24.48 | 2025 | Fisher & Paykel Healthcare |
| Microtransponder, INC. | $22.66 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $20.09 | 2021 | |
| Tactile Systems Technology INC | $18.18 | 2023 | Entre Plus, Flexitouch Plus |
| Melinta Therapeutics, LLC | $17.32 | 2021 | |
| Lundbeck LLC | $17.09 | 2022 | |
| Medtronic, INC. | $16.60 | 2023 | Illumisite |
| Hikma Pharmaceuticals USA | $15.68 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.